ABSTRACT
In an open, pilot study, the efficancy and safety of ursodeoxycholic acid (UDCA) in the treatment of intrahepatic cholestasis of pregnancy was investigated. four patients received 1 g/ñday of UDCA during 20 days and another 2 patients received identical periods of treatment separated by a 14-day interval free of drug. Pruritus and serum levels of toal bile salts and glutamic-pyruvic transaminase improved significantly during treatment with UDCA. Although pruritus and the laboratory alterations had a relapse in the second week after UDCA was discontinued, they improved again in the patients who received a second treatment with UDCA. No adverse reactions were detected in the mothers or in their babies. All neuborns are thriving normally, in a follow-up lasted 3 to 6 months after delivery. It is concluded that UDCA appears to be safe when administered in late pregnancy; its primising efficacy in the treatment of intrahepatic cholestasis of pregnancy should now be confirmed in controlled clinical trials
Subject(s)
Pregnancy , Humans , Female , Adult , Ursodeoxycholic Acid/therapeutic use , Cholestasis, Intrahepatic/drug therapy , Pregnancy Complications/drug therapy , Bile Acids and Salts/blood , Pilot Projects , Follow-Up Studies , Alanine Transaminase/blood , Ursodeoxycholic Acid/administration & dosageABSTRACT
Se analizan los antecedentes clínicos de 51 pacientes con cáncer de ovario, estudiadas y tratadas en el Servicio de Obstetricia y Ginecología del Hospital del Salvador, entre diciembre de 1980 y diciembre de 1986. El diagnóstico se efectuó en etapas avanzadas en 68,2% de los casos, siendo los tumores de origen epitelial la variedad predominante, en el 78,3%. Se desarrolló un protocolo operatorio preestablecido en forma completa en el 82,3%, y se analizan las principales complicaciones postoperatorias. La terapia complementaria predominante fue quimioterapia, que se efectuó en 23 de 27 casos. La tasa de mortalidad en el tiempo de seguimiento alcanza al 8,3% en etapa I; 25% en etapa II; 35% en etapa III, y 70% en etapa IV. En 12 pacientes se ha efectuado revisión de "segundo vistazo", evidenciándose ausencia de enfermedad en sólo la mitad de los casos